We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Efpeglenatideis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Efpeglenatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2019–2024 with a typical study size of 3,983 participants.
Based on 7 studies · 2 meta-analyses · 4 RCTs · 36,108 total participants
Confidence
HighBy outcome
Efpeglenatide has an evidence score of 4.3/10 — emerging evidence based on 7 indexed studies, including 2 meta-analyses. An investigational once-weekly injectable, exendin-based (exenatide-lineage) GLP-1 receptor agonist most famous for the AMPLITUDE-O cardiovascular-outcomes trial — the first to show that an EXENDIN-based (rather than human-GLP-1-based) agonist reduces major adverse cardiovascular events AND kidney-outcome events in high-risk type 2 diabetes. Honest framing: in AMPLITUDE-O (NEJM 2021, n=4,076) efpeglenatide cut MACE by ~27% and a composite kidney outcome by ~32% versus placebo, and across its phase-2/3 program it lowered HbA1c (up to ~1.0-1.2%) and bodyweight (placebo-adjusted up to ~7 kg in obesity without diabetes). BUT it is INVESTIGATIONAL and not FDA-approved or marketed anywhere; the proven benefits are metabolic and cardiorenal (HbA1c, weight, MACE, kidney) — NOT a demonstrated lifespan/longevity outcome. It carries the full GLP-1-class GI side-effect burden (very common dose-dependent nausea, vomiting, diarrhea). It is a prescription-pathway investigational drug, not a dietary supplement, and grey-market 'efpeglenatide' is especially risky. Representative study: PMID 34877513.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Efpeglenatide (LY3298176-class exendin-based GLP-1 receptor agonist)
An investigational once-weekly injectable, exendin-based (exenatide-lineage) GLP-1 receptor agonist most famous for the AMPLITUDE-O cardiovascular-outcomes trial — the first to show that an EXENDIN-based (rather than human-GLP-1-based) agonist reduces major adverse cardiovascular events AND kidney-outcome events in high-risk type 2 diabetes. Honest framing: in AMPLITUDE-O (NEJM 2021, n=4,076) efpeglenatide cut MACE by ~27% and a composite kidney outcome by ~32% versus placebo, and across its phase-2/3 program it lowered HbA1c (up to ~1.0-1.2%) and bodyweight (placebo-adjusted up to ~7 kg in obesity without diabetes). BUT it is INVESTIGATIONAL and not FDA-approved or marketed anywhere; the proven benefits are metabolic and cardiorenal (HbA1c, weight, MACE, kidney) — NOT a demonstrated lifespan/longevity outcome. It carries the full GLP-1-class GI side-effect burden (very common dose-dependent nausea, vomiting, diarrhea). It is a prescription-pathway investigational drug, not a dietary supplement, and grey-market 'efpeglenatide' is especially risky.
Efpeglenatide has unusually strong human cardiorenal evidence for an investigational drug — the pivotal AMPLITUDE-O trial showed reduced MACE and kidney-outcome events plus consistent HbA1c and weight benefit across its phase-2/3 program — but it is NOT approved or marketed anywhere, its proven benefits are metabolic/cardiorenal rather than a demonstrated longevity outcome, and it carries the full GLP-1-class GI side-effect burden, so it stays Emerging.
Efpeglenatide (development codes LY3298176 / HM11260C) is a long-acting, once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist developed by Hanmi Pharmaceutical and Sanofi.
It is mechanistically distinct from the dominant GLP-1 drugs in one important way: semaglutide, liraglutide, and dulaglutide are structurally modelled on human GLP-1, whereas efpeglenatide is EXENDIN-based — an exendin-4 (exenatide-lineage) backbone fused to a human IgG4 Fc fragment via a flexible linker (Hanmi's 'LAPSCOVERY' technology), which extends its half-life to support weekly dosing.
That distinction is the entire reason efpeglenatide matters scientifically: it was widely assumed that the cardiovascular benefit of GLP-1 agonists might be limited to the human-GLP-1-based agents, and AMPLITUDE-O was the trial that tested — and refuted — that hypothesis for an exendin-based drug.
Mechanistically efpeglenatide hits the same GLP-1 receptor cascade as the rest of the class: glucose-dependent insulin secretion with glucagon suppression in the pancreas (lowering HbA1c with low intrinsic hypoglycemia risk), central appetite suppression and satiety (driving weight loss), and slowed gastric emptying (blunting post-meal glucose and contributing to the dose-dependent nausea).
The clinical evidence is genuinely strong but the drug never reached market.
The pivotal trial is AMPLITUDE-O (Gerstein et al., N Engl J Med 2021; n=4,076), a randomized placebo-controlled cardiovascular-outcomes trial in people with type 2 diabetes who had a history of cardiovascular disease or kidney disease plus another risk factor: weekly efpeglenatide (4 or 6 mg) reduced the primary MACE outcome (nonfatal MI, nonfatal stroke, or cardiovascular/undetermined death) by 27% (HR 0.73, 95% CI 0.58-0.92; P=0.007 for superiority) and reduced a composite kidney outcome (worsening kidney function or new macroalbuminuria) by 32% (HR 0.68, 95% CI 0.57-0.79; P<0.001) — and a prespecified epidemiological analysis (Gerstein et al., Diabetes Obes Metab 2024) showed the cardiorenal benefit held across the full spectrum of baseline kidney disease (all interaction P≥0.26).
The earlier dose-finding and efficacy program established the metabolic signal: in early type 2 diabetes referenced to liraglutide (Rosenstock et al., Diabetes Care 2019; 'EXCEED 203', n≈254) efpeglenatide ≥1 mg lowered HbA1c by a placebo-adjusted 0.6-1.2% and was noninferior to liraglutide at the 4 mg dose; in obesity WITHOUT diabetes (Pratley et al., Diabetes Obes Metab 2019, phase-2, n=297) it produced placebo-adjusted weight loss of about 6.3-7.2 kg over 20 weeks; and AMPLITUDE-M (Frias et al., Diabetes Care 2022, phase-3 monotherapy, n≈480) showed dose-dependent HbA1c reductions up to ~1.0% placebo-adjusted with weight loss.
A 2024 systematic review and meta-analysis (Qazi et al., 11 studies) pooled HbA1c -0.84%, bodyweight -2.24 kg and BMI -1.61 kg/m2 versus placebo, with a moderate increase in GI adverse events, and a GLP-1-class network meta-analysis (Vosoughi et al., EClinicalMedicine 2021, 64 RCTs) placed efpeglenatide's weight effect within the class (point estimate ~-3.2 kg over placebo, with semaglutide 2.4 mg the clear leader).
The honest counterweight is decisive on regulatory status: despite this strong cardiorenal dataset, efpeglenatide is INVESTIGATIONAL — it is not FDA-approved or marketed anywhere (its development was not carried through to approval), so it is not a treatment you can be prescribed.
Its proven effects are metabolic and cardiorenal (HbA1c, weight, MACE, kidney) — there is NO demonstrated lifespan/healthspan or longevity outcome; framing it as a longevity drug would be reading a cardiovascular/renal endpoint as something it is not.
Adverse effects are class-typical: dose-related gastrointestinal events (nausea, vomiting, diarrhea, constipation, bloating were more frequent than placebo in AMPLITUDE-O and drove some discontinuation), the GLP-1-class thyroid C-cell (medullary carcinoma) warning is expected to apply, and the usual incretin cautions around pancreatitis, gallbladder events, and lean-mass loss alongside fat loss are unresolved by long-term data.
Because it is an unapproved investigational drug, grey-market 'efpeglenatide' sold online carries serious identity, purity, sterility, and dosing risks with no clinical oversight. It is listed here for reference only and is sandboxed out of goal-based and stack recommendations.
An exendin-4 (exenatide-lineage) GLP-1 receptor agonist fused to a human Fc fragment for a long half-life and weekly dosing — mechanistically distinct from the human-GLP-1-based agents (semaglutide, liraglutide). The single upstream target driving all downstream metabolic and cardiorenal effects; AMPLITUDE-O is notable because it proved an exendin-based agonist also lowers cardiovascular events.
Stimulates pancreatic insulin release in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk (few hypoglycemia events in the trials).
Acts on central appetite-regulating circuits to increase satiety and reduce food intake — the primary driver of the weight loss seen in the obesity and diabetes trials.
Beyond glucose lowering, efpeglenatide reduced major adverse cardiovascular events and a composite kidney outcome (worsening kidney function / new macroalbuminuria) in AMPLITUDE-O — the GLP-1-class cardiorenal benefit, here demonstrated for an exendin-based agent across the spectrum of baseline kidney disease.
How Efpeglenatide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
INVESTIGATIONAL — NO approved or consumer dose. In trials, efpeglenatide was given as a once-weekly subcutaneous injection, titrated up to 4-6 mg (AMPLITUDE-O used 4 and 6 mg) with gradual escalation to limit GI side effects. Not for self-administration; it is an unapproved, unmarketed investigational drug.
Loading: Dose was escalated gradually in trials (stepping up over weeks toward the 4-6 mg maintenance dose) specifically to reduce gastrointestinal side effects — done under trial supervision, never self-titrated.
Can be taken without food
| Form | Type |
|---|---|
| 💊Once-weekly subcutaneous injection (investigational only) | Recommended |
Subcutaneous once-weekly is the only studied route. No approved or marketed formulation exists; unregulated grey-market 'efpeglenatide' vials are not the clinical-trial product and carry no identity, purity, or sterility guarantee.
Minimum: 12 weeks
Optimal: 56 weeks
Cycling: Not required
Note: Once-weekly subcutaneous injection with gradual dose escalation in trials. Not a daily supplement and not an approved/marketed product — there is no consumer dosing schedule.
Dose-response data unavailable. The current published research for Efpeglenatide does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In AMPLITUDE-O (n=4,076, high-risk type 2 diabetes), weekly efpeglenatide reduced the primary MACE composite (nonfatal MI, nonfatal stroke, CV/undetermined death) by 27% vs placebo (HR 0.73; P=0.007 for superiority) — the first exendin-based GLP-1 agonist to show this. A cardiovascular outcome, not a longevity outcome.
AMPLITUDE-O also reduced a composite kidney outcome (decreased kidney function or new macroalbuminuria) by 32% vs placebo (HR 0.68; P<0.001), and a follow-up analysis showed this benefit was independent of baseline kidney-disease category.
Dose-dependent HbA1c reductions across the program — placebo-adjusted up to ~1.0-1.2% (AMPLITUDE-M monotherapy; EXCEED 203 noninferior to liraglutide at 4 mg); pooled meta-analysis HbA1c -0.84% vs placebo.
In obesity WITHOUT diabetes (phase-2, Pratley et al. 2019, n=297) efpeglenatide produced placebo-adjusted weight loss of ~6.3-7.2 kg over 20 weeks; weight reductions were also seen in the diabetes trials. Within-class point estimate (~-3.2 kg over placebo) sits below high-dose semaglutide.
Nausea, vomiting, diarrhea, constipation and bloating were more frequent than placebo (especially during dose escalation) and drove some treatment discontinuation. Class-typical for GLP-1 agonists.
Despite strong cardiorenal trial data, efpeglenatide was not carried to approval and is not marketed anywhere; it is not a prescribable treatment, and long-term outcomes beyond the trial windows are not established. Listed here for reference only.
There is no approved or marketed use; obtaining or using grey-market 'efpeglenatide' means taking an unapproved investigational drug with no clinical oversight, dosing standard, or product-quality guarantee. Strongly discouraged.
Higher hypoglycemia risk if combined; only relevant under trial-level medical supervision with secretagogue adjustment.
Expected to be contraindicated — the GLP-1 class carries a thyroid C-cell tumor warning.
Contraindicated — weight loss and an investigational drug are not appropriate in pregnancy or breastfeeding.
GLP-1 agonism slows gastric emptying, which can reduce the rate/extent of absorption of co-administered oral drugs — relevant for time-critical or narrow-therapeutic-index oral medicines.
Combining a glucose-lowering incretin agonist with insulin or sulfonylureas increases hypoglycemia risk; dose reduction of the secretagogue is typically required in supervised use. Efpeglenatide alone showed few hypoglycemia events.
Tip: Dose-related and more common than placebo; mitigated by a lower starting dose and slow escalation. Generally transient, concentrated during titration.
Tip: Class-typical GI effects (more frequent than placebo in AMPLITUDE-O); generally transient and dose-related; a reason for some discontinuation.
Tip: Higher than placebo in the weight-management trial (5-19% across dose cohorts); slower titration may help.
Tip: Rapid weight loss and incretin-class effects are associated with gallbladder events; report severe abdominal pain.
The commonly studied dose of Efpeglenatide is INVESTIGATIONAL — NO approved or consumer dose. In trials, efpeglenatide was given as a once-weekly subcutaneous injection, titrated up to 4-6 mg (AMPLITUDE-O used 4 and 6 mg) with gradual escalation to limit GI side effects. Not for self-administration; it is an unapproved, unmarketed investigational drug.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Efpeglenatide — consistent daily use matters more than the time of day. Trials dosed once weekly subcutaneously with gradual dose escalation to limit gastrointestinal effects; the long half-life supports once-weekly administration.
Efpeglenatide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea / vomiting, diarrhea / constipation / bloating, treatment discontinuation due to GI events. Use caution if any of these apply to you: Not a dietary supplement and not an approved/marketed drug — investigational; do not self-source grey-market vials; Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell warning); History of pancreatitis.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Delays gastric emptying, blunting post-meal glucose excursions and prolonging fullness — and the mechanism behind much of the dose-dependent nausea seen early in treatment.
Stacking efpeglenatide with another GLP-1/incretin agonist (semaglutide, liraglutide, dulaglutide, tirzepatide) compounds gastrointestinal toxicity and glucose-lowering with no evidence of added benefit; this combination is not studied and is dangerous.
Tip: A class concern for incretin drugs; discontinue and seek care for persistent severe abdominal pain. Long-term incidence not established.